当前位置： SCI文献检索 > Cancer Immunology Research期刊下所有文献 > Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Abstract：

:Several host factors may affect the spread of cancer to distant organs; however, the intrinsic role of dendritic cells (DC) in controlling metastasis is poorly described. Here, we show in several tumor models that although the growth of primary tumors in Batf3-deficient mice, which lack cross-presenting DCs, was not different from primary tumors in wild-type (WT) control mice, Batf3-deficient mice had increased experimental and spontaneous metastasis and poorer survival. The increased metastasis was independent of CD4+ and CD8+ T lymphocytes, but required NK cells and IFNγ. Chimeric mice in which Batf3-dependent DCs uniformly lacked the capacity to produce IL12 had metastatic burdens similar to the Batf3-deficient mice, suggesting that Batf3+ DCs were the only cell type whose IL12 production was critical for controlling metastasis. We found that IL12-YFP reporter mice, whose lungs were injected with B16F10 melanoma, had increased numbers of IL12-expressing CD103+ DCs with enhanced CD86 expression. Bone-marrow-derived DCs from WT, but not Batf3-deficient, mice activated NK cells to produce IFNγ in an IL12-dependent manner and therapeutic injection of recombinant mouse IL12 decreased metastasis in both WT and Batf3-deficient mice. Analysis of TCGA datasets revealed an association between high expression of BATF3 and IRF8 and improved survival of breast cancer patients; BATF3 expression also significantly correlated with NK-cell receptor genes, IL12, and IFNG Collectively, our findings show that IL12 from CD103+ DCs is critical for NK cell-mediated control of tumor metastasis. Cancer Immunol Res; 5(12); 1098-108. ©2017 AACR.

journal_name

Cancer Immunol Res

journal_title

Cancer immunology research

authors

Mittal D,Vijayan D,Putz EM,Aguilera AR,Markey KA,Straube J,Kazakoff S,Nutt SL,Takeda K,Hill GR,Waddell N,Smyth MJ

doi

10.1158/2326-6066.CIR-17-0341

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

1098-1108

issue

12

eissn

2326-6066

issn

2326-6074

pii

2326-6066.CIR-17-0341

journal_volume

5

pub_type

杂志文章

相关文献

Cancer Immunology Research文献大全
  • Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.

    abstract：:Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,评审

    doi：10.1158/2326-6066.CIR-15-0194

    authors： Gilboa E,Berezhnoy A,Schrand B

    更新日期：2015-11-01 00:00:00

  • Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.

    abstract：:Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phenomena, we strategically chose five clinical-stage immuno-oncology age...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-20-0638

    authors： Fabian KP,Malamas AS,Padget MR,Solocinski K,Wolfson B,Fujii R,Abdul Sater H,Schlom J,Hodge JW

    更新日期：2020-12-22 00:00:00

  • Sustained Type I Interferon Reinforces NK Cell-Mediated Cancer Immunosurveillance during Chronic Virus Infection.

    abstract：:The importance of natural killer (NK) cells in the early immune response to viral or bacterial infection is well known. However, the phenotype, function, and physiologic role of NK cells during the late stage of persistent viral infection have not been extensively studied. Here, we characterized NK cells in mice persi...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0403

    authors： Oh JH,Kim MJ,Choi SJ,Ban YH,Lee HK,Shin EC,Lee KM,Ha SJ

    更新日期：2019-04-01 00:00:00

  • Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

    abstract：:Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0089

    authors： Tsuji T,Sabbatini P,Jungbluth AA,Ritter E,Pan L,Ritter G,Ferran L,Spriggs D,Salazar AM,Gnjatic S

    更新日期：2013-11-01 00:00:00

  • Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

    abstract：:In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case tha...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0605

    authors： Kaseb AO,Vence L,Blando J,Yadav SS,Ikoma N,Pestana RC,Vauthey JN,Allison JP,Sharma P

    更新日期：2019-09-01 00:00:00

  • Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

    abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0200-T

    authors： Jhaveri DT,Kim MS,Thompson ED,Huang L,Sharma R,Klein AP,Zheng L,Le DT,Laheru DA,Pandey A,Jaffee EM,Anders RA

    更新日期：2016-03-01 00:00:00

  • Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

    abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,评审

    doi：10.1158/2326-6066.CIR-14-0075

    authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

    更新日期：2014-07-01 00:00:00

  • Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

    abstract：:Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti-PD-1, with and without ipilimumab (anti-CTLA-4), and identified 31 patients w...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,多中心研究

    doi：10.1158/2326-6066.CIR-18-0717

    authors： Johnson DB,Taylor KB,Cohen JV,Ayoubi N,Haugh AM,Wang DY,Schlick BD,Voorhees AL,Gage KL,Fintelmann FJ,Sullivan RJ,Eroglu Z,Abramson RG

    更新日期：2019-11-01 00:00:00

  • CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

    abstract：:The transcription factor T-bet controls the Th1 genetic program in T cells for effective antitumor responses. Anti-CTLA-4 immunotherapy elicits dramatic antitumor responses in mice and in human patients; however, factors that regulate T-bet expression during an antitumor response mediated by anti-CTLA-4 remain to be e...

    journal_title：Cancer immunology research

    pub_type： 临床试验,杂志文章

    doi：10.1158/2326-6066.CIR-13-0155

    authors： Chen H,Fu T,Suh WK,Tsavachidou D,Wen S,Gao J,Ng Tang D,He Q,Sun J,Sharma P

    更新日期：2014-02-01 00:00:00

  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

    abstract：:Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0158

    authors： Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

    更新日期：2014-09-01 00:00:00

  • Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.

    abstract：:Cancer-testis (CT) antigens are attractive tumor antigens for cancer immunotherapy. They comprise a group of proteins normally expressed in germ cells and aberrantly activated in a variety of human cancers. The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0124

    authors： Chen YT,Panarelli NC,Piotti KC,Yantiss RK

    更新日期：2014-05-01 00:00:00

  • Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

    abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0675

    authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

    更新日期：2018-06-01 00:00:00

  • CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

    abstract：:CD137 (4-1BB) costimulation imprints long-term changes that instruct the ultimate behavior of T cells that have previously experienced CD137 ligation. Epigenetic changes could provide a suitable mechanism for these long-term consequences. Genome-wide DNA methylation arrays were carried out on human peripheral blood CD...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0159

    authors： Aznar MA,Labiano S,Diaz-Lagares A,Molina C,Garasa S,Azpilikueta A,Etxeberria I,Sanchez-Paulete AR,Korman AJ,Esteller M,Sandoval J,Melero I

    更新日期：2018-01-01 00:00:00

  • IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities.

    abstract：:The cytokine IL15 is required for survival and activation of natural killer (NK) cells as well as expansion of NK-cell populations. Here, we compare the effects of continuous IL15 infusions on NK-cell subpopulations in cancer patients. Infusions affected the CD56bright NK-cell subpopulation in that the expansion rates...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0279

    authors： Dubois S,Conlon KC,Müller JR,Hsu-Albert J,Beltran N,Bryant BR,Waldmann TA

    更新日期：2017-10-01 00:00:00

  • An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

    abstract：:A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclon...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0115

    authors： Golden EB,Demaria S,Schiff PB,Chachoua A,Formenti SC

    更新日期：2013-12-01 00:00:00

  • Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.

    abstract：:The presence and activity of CD8+ T cells within the tumor microenvironment are essential for the control of tumor growth. Utilizing B16-F10 melanoma tumors that express altered peptide ligands of chicken ovalbumin, OVA257-264, we measured high- and low-affinity OVA-specific responses following adoptive transfer of OT...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0690

    authors： Snook JP,Soedel AJ,Ekiz HA,O'Connell RM,Williams MA

    更新日期：2020-04-01 00:00:00

  • Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.

    abstract：:Despite HER2-targeted therapies improving the outcome of HER2+ breast cancer, many patients experience resistance and metastatic progression. Cancer stem cells (CSC) play a role in this resistance and progression, thus combining HER2 targeting with CSC inhibition could improve the management of HER2+ breast cancer. Th...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-20-0082

    authors： Conti L,Bolli E,Di Lorenzo A,Franceschi V,Macchi F,Riccardo F,Ruiu R,Russo L,Quaglino E,Donofrio G,Cavallo F

    更新日期：2020-08-01 00:00:00

  • Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

    abstract：:New immunotherapeutic strategies are needed to induce effective antitumor immunity in all cancer patients. Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies. Infiltration of tumor-associated macrophages (TAM) is prominent in mesothelioma and is linked to immune suppre...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0309

    authors： Dammeijer F,Lievense LA,Kaijen-Lambers ME,van Nimwegen M,Bezemer K,Hegmans JP,van Hall T,Hendriks RW,Aerts JG

    更新日期：2017-07-01 00:00:00

  • Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.

    abstract：:Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0180

    authors： Turcotte S,Katz SC,Shia J,Jarnagin WR,Kingham TP,Allen PJ,Fong Y,D'Angelica MI,DeMatteo RP

    更新日期：2014-06-01 00:00:00

  • T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.

    abstract：:MHC-bound peptides from aberrant proteins may be a specific immunotherapeutic target on cancer cells. Because of difficulties in identifying such antigens, viral or model antigens have so far been used to study their biological relevance. We here identify a naturally existing human T-cell epitope derived from a trunca...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0137

    authors： Pont MJ,Oostvogels R,van Bergen CAM,van der Meijden ED,Honders MW,Bliss S,Jongsma MLM,Lokhorst HM,Falkenburg JHF,Mutis T,Griffioen M,Spaapen RM

    更新日期：2019-05-01 00:00:00

  • Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

    abstract：:The "cancer immunogenomics" paradigm has facilitated the search for tumor-specific antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen discovery. We applied this methodology to identify tumor-specific "neoantigens" in the C57BL/6-derived GL261 and VM/Dk-derived SMA-560 tumor model...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0156

    authors： Johanns TM,Ward JP,Miller CA,Wilson C,Kobayashi DK,Bender D,Fu Y,Alexandrov A,Mardis ER,Artyomov MN,Schreiber RD,Dunn GP

    更新日期：2016-12-01 00:00:00

  • Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer.

    abstract：:CD47-specific antibodies and fusion proteins that block CD47-SIRPα signaling are employed as antitumor agents for several cancers. Here, we investigated the synergistic antitumor effect of simultaneously targeting CD47 and autophagy in non-small cell lung cancer (NSCLC). SIRPαD1-Fc, a novel CD47-targeting fusion prote...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0398

    authors： Zhang X,Fan J,Wang S,Li Y,Wang Y,Li S,Luan J,Wang Z,Song P,Chen Q,Tian W,Ju D

    更新日期：2017-05-01 00:00:00

  • YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.

    abstract：:Activation of YAP, a Hippo pathway effector, is an important resistance mechanism to BRAF inhibitor (BRAFi) in melanoma. Emerging evidence also suggests that YAP is involved in suppression of the antitumor immune response. However, the potential direct impact of YAP activity on cytotoxic T-cell immune responses has no...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0320

    authors： Kim MH,Kim CG,Kim SK,Shin SJ,Choe EA,Park SH,Shin EC,Kim J

    更新日期：2018-03-01 00:00:00

  • Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

    abstract：:Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0012

    authors： Hansmann L,Han A,Penter L,Liedtke M,Davis MM

    更新日期：2017-09-01 00:00:00

  • Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

    abstract：:Granulocytic-macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients wi...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0042

    authors： Wei XX,Chan S,Kwek S,Lewis J,Dao V,Zhang L,Cooperberg MR,Ryan CJ,Lin AM,Friedlander TW,Rini B,Kane C,Simko JP,Carroll PR,Small EJ,Fong L

    更新日期：2016-11-01 00:00:00

  • Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

    abstract：:Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0358

    authors： Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

    更新日期：2018-03-01 00:00:00

  • IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors.

    abstract：:We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1β-/-, IL1α-/-, and IL1R1-/- mice. Tumors grew progressively in IL1R-/- and IL1α-/- mice but were often absent in IL1β-/- mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0552

    authors： Tian T,Lofftus S,Pan Y,Stingley CA,King SL,Zhao J,Pan TY,Lock R,Marglous JW,Liu K,Widlund HR,Fuhlbrigge RC,Cichowski K,Kupper TS

    更新日期：2020-05-01 00:00:00

  • Immunological Mechanisms Underneath the Efficacy of Cancer Therapy.

    abstract：:Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents-including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy-depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunosti...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,评审

    doi：10.1158/2326-6066.CIR-16-0197

    authors： Galluzzi L,Zitvogel L,Kroemer G

    更新日期：2016-11-01 00:00:00

  • Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.

    abstract：:The prognosis is very dismal for patients with relapsed CD20(+) B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20(+) B-NHL. In this study, we investigated functional activities of anti...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0114

    authors： Chu Y,Hochberg J,Yahr A,Ayello J,van de Ven C,Barth M,Czuczman M,Cairo MS

    更新日期：2015-04-01 00:00:00

  • Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.

    abstract：:In the context of cancer, naïve T cells are insufficiently primed and become progressively dysfunctional. Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable clinical responses only in a limited proportion of cancer patients, suggesting that other pathways must be targeted to improve clinical ef...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0103-T

    authors： Bransi A,Salgado OC,Beffinger M,Milo K,Silina K,Yagita H,Becher B,Knuth A,van den Broek M

    更新日期：2015-11-01 00:00:00